New substituted indolinones, their manufacture and their use as medicaments
申请人:Roth Juergen Gerald
公开号:US20050009898A1
公开(公告)日:2005-01-13
The present invention relates to substituted indolinones of general formula
wherein
R
1
to R
6
and X are defined as in claim
1
, the isomers and the salts thereof, in particular the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on various receptor-tyrosine kinases, and cycline/CDK complexes as well as on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
SUBSTITUIERTE INDOLINONE ALS TYROSINKINASE INHIBITOREN
申请人:Boehringer Ingelheim Pharma GmbH & Co.KG
公开号:EP1212318B1
公开(公告)日:2006-01-25
US6794395B1
申请人:——
公开号:US6794395B1
公开(公告)日:2004-09-21
Substituted indolinones, their manufacture and their use as medicaments
申请人:Boehringer Ingelheim Pharma GmbH & Co. KG
公开号:US06794395B1
公开(公告)日:2004-09-21
The present invention relates to substituted indolinones of general formula
wherein
R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, in particular the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on various receptor-tyrosine kinases, and cycline/CDK complexes as well as on the proliferation of endothelial cells and various tumor cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.